Support Order My Page Perform search Procedures Products Testimonials Knowledge Investors About us Blog Contact Vitrolife / Investors / Press releases / 2016 / Vitrolife introduces EmbryoScope+ and broadens time-lapse portfolio VITROLIFE INTRODUCES EMBRYOSCOPE+ AND BROADENS TIME-LAPSE PORTFOLIO 2016-06-27 - 08:30 Vitrolife is the market leader of time-lapse systems for use in assisted reproduction. With the introduction of EmbryoScope+, the company can offer an additional high quality time-lapse system for undisturbed culture and improved selection of embryos. EmbryoScope+ has a large capacity in combination with a small footprint, providing an efficient workflow and optimised usage of clinic resources. The product will be introduced at the upcoming ESHRE conference next week in Helsinki, Finland. EmbryoScope+ is a time-lapse system with an integrated incubator. EmbryoScope+ builds on the same technology as the company´s world-wide used EmbryoScope, but with a larger capacity for 15 patients with up to 16 embryos per patient in a single instrument. The new system has a small footprint, which is an advantage for labs where space is limited. “The time-lapse market is growing and we believe that time-lapse has the potential to become a standard tool in IVF treatments. With the introduction of EmbryoScope+, we will make our time-lapse offer even more flexible”, says Thomas Axelsson, CEO at Vitrolife. Time-lapse technology enables the entire development of the embryo to be studied, increasing the probability of choosing the embryo with the best chances of leading to pregnancy. The use of time-lapse technology has been documented to improve clinical outcomes. Gothenburg, June 27, 2016 VITROLIFE AB (publ) Thomas Axelsson, CEO Queries should be addressed to: Thomas Axelsson, CEO, tel 46 31 721 80 01 Mikael Engblom, CFO, tel 46 31 721 80 14 Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on June 27, 2016 at 08:30 a.m. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. RELATED LINKS Press release in html format Press release in PDF format Vitrolife is committed to improving pregnancy rates. This is why we provide an unbroken chain of quality products, securing the results in every step during the whole IVF-treatment. Only Vitrolife can guarantee every link in this chain. With equally devoted clinics we reach success. Together. All the way. Vitrolife AB (publ) Vitrolife AB (publ) Box 9080 400 92 Göteborg Sweden Tel: +46 31 721 80 00 Fax: +46 31 721 80 99 info@vitrolife.com Visitors/deliveries: Gustaf Werners gata 2 SE-421 32 V. Frölunda Sweden Ordering Tel: +46 31 721 81 00 Fax: +46 31 721 80 90 order@vitrolife.com Follow Vitrolife: Follow Vitrolife on Facebook Follow Vitrolife on Youtube Follow Vitrolife on Linkedin Local contact Vitrolife, Inc. 3601 South Inca Street Englewood CO 80110, USA 6835 Flanders Drive, Suite 500 San Diego CA 92121, USA Englewood (Denver): Phone: +1 303 762 1933 Fax: +1 303 781 5615 San Diego: Phone: +1 800 995 8081 (USA) Phone: +1 858 824 0888 (International) Fax: +1 858 824 0891 Stay updated! We offer several opportunities to stay updated on the latest research, informative blog posts, upcoming events, product focus, events and much more. You are welcome to choose how you would like to be updated. All content © Vitrolife 2015. Products shown on this website might not be available on all markets. View full disclaimer.